Cargando…

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma

BACKGROUND: The interaction of programmed death-1 protein (PD-1) and programmed death-1 ligand (PD-L1) produces immunosuppressive activity, protecting tumor cells from anti-tumor immunity and possibly releasing soluble PD-L1 (sPD-L1) from PD-L1 expressing tumor cells. Therefore, we measured serum le...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Inju, Lee, Hansang, Yoon, Sang Eun, Ryu, Kyung Ju, Ko, Young Hyeh, Kim, Won Seog, Kim, Seok Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020571/ https://www.ncbi.nlm.nih.gov/pubmed/32054467 http://dx.doi.org/10.1186/s12885-020-6612-2

Ejemplares similares

Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients
por: Liu, Shujun, et al.
Publicado: (2020)

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
por: Chang, Boyang, et al.
Publicado: (2018)

The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas
por: Liu, Shujun, et al.
Publicado: (2020)

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
por: Buderath, Paul, et al.
Publicado: (2019)

The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer
por: Shao, Weifang, et al.
Publicado: (2022)

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
por: Kim, Seok Jin, et al.
Publicado: (2022)

Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
por: Bailly, Christian, et al.
Publicado: (2021)

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas
por: Kim, Seok-Jin, et al.
Publicado: (2019)

Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men
por: Katongole, Paul, et al.
Publicado: (2022)

The Change of Soluble Programmed Death Ligand 1 (sPD-L1) in Plasma of Small Cell Lung Cancer and Its Clinical Significance
por: Lu, Feijie, et al.
Publicado: (2022)

Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer
por: Świderska, Janina, et al.
Publicado: (2022)

The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1(+) regulator B cells mediates immunosuppression in triple-negative breast cancer
por: Li, Xuejiao, et al.
Publicado: (2022)

Retracted: The Change of Soluble Programmed Death Ligand 1 (sPD-L1) in Plasma of Small Cell Lung Cancer and Its Clinical Significance
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary study
por: Yang, Jia, et al.
Publicado: (2019)

Soluble programmed death molecule 1 (sPD-1) as a predictor of interstitial lung disease in rheumatoid arthritis
por: Xu, Li, et al.
Publicado: (2021)

Soluble sPD-L1 and Serum Amyloid A1 as Potential Biomarkers for Lung Cancer
por: Jovanović, Dragana, et al.
Publicado: (2019)

Soluble Programmed Death-Ligand 1 (sPD-L1) as a Promising Marker for Head and Neck Squamous Cell Carcinoma: Correlations With Clinical and Demographic Characteristics
por: Alrehaili, Amani A, et al.
Publicado: (2023)

Can sPD-1 and sPD-L1 Plasma Concentrations Predict Treatment Response among Patients with Extraparenchymal Neurocysticercosis?
por: Toledo, Andrea, et al.
Publicado: (2023)

Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma
por: Lee, Hansang, et al.
Publicado: (2019)

Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2023)

FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma
por: Ryu, Kyung Ju, et al.
Publicado: (2016)

The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte
por: Han, Baojuan, et al.
Publicado: (2021)

The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients
por: ANCIN, Burcu, et al.
Publicado: (2022)

Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab–CHOP
por: Hong, Jung Yong, et al.
Publicado: (2017)

Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma
por: Park, Ha Young, et al.
Publicado: (2016)

CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain
por: Cho, Junhun, et al.
Publicado: (2022)

The association between sPD-1 levels versus liver biochemistry and viral markers in chronic hepatitis B patients: a comparative study of different sPD-1 assays
por: Jeng, Wen-Juei, et al.
Publicado: (2022)

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
por: Lee, Boram, et al.
Publicado: (2021)

The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients
por: Kim, Seok Jin, et al.
Publicado: (2015)

Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity
por: Beserra, Danielle Rosa, et al.
Publicado: (2022)

Erratum to: The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients
por: Kim, Seok Jin, et al.
Publicado: (2015)

IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma
por: Heo, Mi Hwa, et al.
Publicado: (2017)

Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism
por: Lim, Sung Hee, et al.
Publicado: (2016)

Soluble programmed cell death receptor-1 (sPD-1): a potential biomarker with anti-inflammatory properties in human and experimental acute respiratory distress syndrome (ARDS)
por: Monaghan, Sean F., et al.
Publicado: (2016)

EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma
por: Lee, Ji Yun, et al.
Publicado: (2021)

Correlation of sPD1 with Procalcitonin and C-Reactive Protein Levels in Patients with Sepsis
por: Bakhshiani, Zahra, et al.
Publicado: (2021)

Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma
por: Yoon, Sang Eun, et al.
Publicado: (2022)

Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma
por: Ham, Jun Soo, et al.
Publicado: (2017)

Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy
por: Maeng, Chi Hoon, et al.
Publicado: (2016)

Serum sPD1 and sPDL1 as Biomarkers for Evaluating the Immune State of Lung Adenocarcinoma Patients
por: Wu, Yumin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g61amp05um5c25nh8befta19f1